| Literature DB >> 31402852 |
Tadashi Watabe1,2, Jun Hatazawa1,2.
Abstract
Resting-state networks (RSNs) exhibit spontaneous functional connectivity in the resting state. Previous studies have evaluated RSNs mainly based on spontaneous fluctuations in blood oxygenation level-dependent (BOLD) signals during functional magnetic resonance imaging (fMRI). However, separation between regional increases in cerebral blood flow (CBF) and oxygen consumption is theoretically difficult using BOLD-fMRI. Such separation can be achieved using quantitative 15O-gas and water positron emission tomography (PET). In addition, 18F-FDG PET can be used to investigate functional connectivity based on changes in glucose metabolism, which reflects local brain activity. Previous studies have highlighted the feasibility and clinical usefulness of 18F-FDG-PET for the analysis of RSNs, and recent studies have utilized simultaneous PET/fMRI for such analyses. While PET provides seed information regarding the focus of the abnormalities (e.g., hypometabolism and reduced target binding), fMRI is used for the analysis of functional connectivity. Thus, as PET and fMRI provide different types of information, integrating these modalities may aid in elucidating the pathological mechanisms underlying certain diseases, and in characterizing individual patients.Entities:
Keywords: PET; blood flow; default mode network; functional connectivity; metabolism
Year: 2019 PMID: 31402852 PMCID: PMC6676772 DOI: 10.3389/fnins.2019.00775
Source DB: PubMed Journal: Front Neurosci ISSN: 1662-453X Impact factor: 4.677
FIGURE 1Significant positive functional correlations involving the DMN. (A) Correlations based on CBF; (B) CMRO2; (C) the overlap between CBF and CMRO2 (reprint from Aoe et al., 2018; permission obtained from the Annals of Nuclear Medicine in accordance with their open access policy).
FIGURE 2Brain responses during activation for each modality.
Main findings of functional connectivity analyses using PET and fMRI.
| A total of 22 healthy, right-handed participants (15 men, 7 women; mean age: 54.5 ± 10.0 years) | ||
| A total of 23 patients with aMCI/AD and 23 healthy older adults | ||
| Amyloid-positive patients with early AD ( | ||
| A total of 16 patients with MDD without comorbidities and 15 healthy controls | ||
| A total of 16 patients with MDD and 14 controls |